SCH 50911

Drug Profile

SCH 50911

Latest Information Update: 17 Sep 2004

Price : $50

At a glance

  • Originator Schering-Plough
  • Class Antidementias; Antiepileptic drugs; Neuroprotectants
  • Mechanism of Action GABA B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Absence epilepsy; Cognition disorders

Most Recent Events

  • 15 Jun 2004 Discontinued for Cognition disorders in USA (unspecified route)
  • 15 Jun 2004 Discontinued - Preclinical for Absence seizures in USA (unspecified route)
  • 25 Aug 1998 No-Development-Reported for Absence seizures in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top